Loading…
Lobbying Spend
$140K
Filings
2
Firms Hired
1
Active Period
2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Biosimilar Red Tape Elimination Act
2026 · third_quarter · Firm: SUN PHARMACEUTICAL INDUSTRIES, INC.
H.R. 5526 - Biosimilar Red Tape Elimination Act; all provisions. S. 1414 - Expedited Access to Biosimilars Act; all provisions. S. 2658 - Medication Affordability and Patent Integrity Act; all provisions.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 5526
Expedited Access to Biosimilars Act
2026 · third_quarter · Firm: SUN PHARMACEUTICAL INDUSTRIES, INC.
H.R. 5526 - Biosimilar Red Tape Elimination Act; all provisions. S. 1414 - Expedited Access to Biosimilars Act; all provisions. S. 2658 - Medication Affordability and Patent Integrity Act; all provisions.
Client expense: $140,000 · Firm income: —
Matched citations: S. 1414
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Firm: SUN PHARMACEUTICAL INDUSTRIES, INC.
H.R. 5526 - Biosimilar Red Tape Elimination Act; all provisions. S. 1414 - Expedited Access to Biosimilars Act; all provisions. S. 2658 - Medication Affordability and Patent Integrity Act; all provisions.
Client expense: $140,000 · Firm income: —
Matched citations: S. 2658
Source: Senate LDA